Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Jangchul Park

EGFR Exon 19 Insertions Show Good Response to Gefitinib, but Short Time to Progression in Japanese Patients

Journal of Thoracic Oncology

English

Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK Among Treatment-Naïve Patients With Advanced Lung Adenocarcinoma

PLoS ONE

Multidisciplinary

2016

English

Related publications

EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma

Clinical Cancer Research

Cancer Research

Oncology

2011

English

Two Sides of the Same Coin: EGFR Exon 19 Deletions and Insertions in Lung Cancer

Clinical Cancer Research

Cancer Research

Oncology

2012

English

MA15.05 the Mutational Profiles of EGFR 19 Exon Deletion and 21 Exon L858R Mutation and Their Association With Primary Response to EGFR-TKIs

Journal of Thoracic Oncology

English

P3.13-13 Afatinib in Lung Adenocarcinoma Harboring De Novo EGFR Exon 20 Insertions.

Journal of Thoracic Oncology

English

Learning From Errors: Response to Gefitinib in Kidney Urothelial Carcinoma With EGFR Mutations

English

Central Nervous System Progression in Advanced Non–small Cell Lung Cancer Patients With EGFR Mutations in Response to First-Line Treatment With Two EGFR-TKIs, Gefitinib and Erlotinib: A Comparative Study

English

Erlotinib Has Better Efficacy Than Gefitinib in Adenocarcinoma Patients Without EGFR-activating Mutations, but Similar Efficacy in Patients With EGFR-activating Mutations

Experimental and Therapeutic Medicine

English

Parkinson's Patients Show Positive Response to Implants

Nature

Multidisciplinary

2002

English

P1.15-05 the Frequency and Spectrum of EGFR Exon 20 Insertions in NSCLC: A Global Literature Review

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Jangchul Park

EGFR Exon 19 Insertions Show Good Response to Gefitinib, but Short Time to Progression in Japanese Patients

Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK Among Treatment-Naïve Patients With Advanced Lung Adenocarcinoma

Related publications

EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma

Two Sides of the Same Coin: EGFR Exon 19 Deletions and Insertions in Lung Cancer

MA15.05 the Mutational Profiles of EGFR 19 Exon Deletion and 21 Exon L858R Mutation and Their Association With Primary Response to EGFR-TKIs

P3.13-13 Afatinib in Lung Adenocarcinoma Harboring De Novo EGFR Exon 20 Insertions.

Learning From Errors: Response to Gefitinib in Kidney Urothelial Carcinoma With EGFR Mutations

Central Nervous System Progression in Advanced Non–small Cell Lung Cancer Patients With EGFR Mutations in Response to First-Line Treatment With Two EGFR-TKIs, Gefitinib and Erlotinib: A Comparative Study

Erlotinib Has Better Efficacy Than Gefitinib in Adenocarcinoma Patients Without EGFR-activating Mutations, but Similar Efficacy in Patients With EGFR-activating Mutations

Parkinson's Patients Show Positive Response to Implants

P1.15-05 the Frequency and Spectrum of EGFR Exon 20 Insertions in NSCLC: A Global Literature Review